Treatment of OS tumors using 188Rhenium (188Re) and 177Lutetium (177Lu)-labeled IGF2R-specific mAbs MEM-238 and 2G11 resulted in tumor growth inhibition and possibly regression while being safe to normal organs. This evidence concerns the gene IGF2R and neoplasm.